CNO Filings — Cno Financial Group, Inc. - FilingSpy
CNO
Cno Financial Group, Inc.
A holding company that develops and administers health, annuity, and life insurance for middle-income Americans near or in retirement, sold through brands like Bankers Life, Colonial Penn, and Washington National. Founded in 1979 as Security National of Indiana Corp., it grew through acquisitions as Conseco before renaming itself CNO in 2010—taking the name from its own stock ticker symbol. Its Colonial Penn brand traces to a founder who also co-founded AARP.
CNO raises full-year operating EPS guidance to $4.60–$4.80 as insurance margins and investment income climb.
CNO's insurance business delivered its highest product margin in over a year. rose 11.6% to $1,285.2 million and climbed 37% to $119.5 million, driven by an 11% increase in total insurance product margin and a 46% rise in unallocated investment income. Management raised its full-year operating outlook, signaling confidence the can continue.
Key takeaways
rose 37% to $119.5 million, as total insurance product margin grew 11% to $279.0 million and investment income not allocated to product lines increased 46% to $49.4 million.
Health margin rose 10% to $147.2 million on Medicare supplement growth and favorable morbidity, while life margin increased 12% to $71.2 million on lower advertising expense, business growth, and lower traditional life mortality.
Annuity margin grew 11% to $60.6 million, led by fixed indexed annuities where benefited from block growth and higher spread rates.
Section summaries
Management's Discussion and Analysis
CNO Q2 2026 net operating income rose 37% to $119.5M, driven by higher insurance product margins and investment income.
⌄
Total grew 11% to $279.0M, with health margin up 10% to $147.2M on Medicare supplement growth and favorable .
Full-year 2026 operating was raised to $4.60–$4.80 from the prior $4.25–$4.45, and the expense ratio outlook was narrowed to 18.8%–19.0%.
Reported was $125.9 million, up 37.1% , while rose 46.2% to $1.33, aided by a lower share count from ongoing repurchases.
Holding company liquidity stood at $233.2 million, above the $150 million minimum target, with $300.4 million remaining in authorization.
What changed
The prior quarter flagged annuity margin to watch as the fixed indexed annuity block grew: annuity margin rose to $60.6 million from $58.5 million in Q1 2026, with benefiting from block growth and higher spread rates.
Health margin durability was a watch item as favorable morbidity could reverse: health margin rose to $147.2 million from $132.6 million in Q1 2026, with Medicare supplement growth and continued favorable morbidity driving the increase.
The Worksite fee services exit, expected to be substantially complete in H1 2026, was flagged for its effect on the expense ratio: the narrowed 18.8%–19.0% expense ratio outlook suggests the exit is progressing without disrupting the cost structure.
Full-year 2026 operating was raised to $4.60–$4.80, up from the $4.25–$4.45 set after FY 2025, reflecting the strength in insurance margins and investment income seen in the first half.
What to watch
Q3 2026 annuity margin against the $60.6 million posted this quarter, as the fixed indexed annuity block grows but the annual actuarial review in Q3 could introduce a one-off benefit or .
Health margin trajectory as Medicare supplement growth and favorable morbidity continue, testing whether the improvement is durable or reflects a temporary claims environment.
Full-year 2026 operating against the raised $4.60–$4.80 guide, with first-half of $220.8 million needing a second-half contribution consistent with the higher target.
Progress on the Worksite fee services exit and its effect on the expense ratio, as the narrowed 18.8%–19.0% outlook implies the exit is on track for H1 2026 completion.
Annuity margin increased 11% to $60.6M, led by fixed indexed annuities where benefited from block growth and higher spread rates.
Life margin rose 12% to $71.2M, reflecting lower advertising expense, business growth, and lower mortality in traditional life.
Investment income not allocated to product lines surged 46% to $49.4M, primarily due to higher alternative investment returns and increased FHLB/FABN .
Full-year 2026 operating was raised to $4.60-$4.80, and the expense ratio outlook was narrowed to 18.8%-19.0%.
Holding company liquidity stood at $233.2M, above the $150M minimum target, with $300.4M remaining in authorization.
Quantitative and Qualitative Disclosures About Market Risk
Our market risks, and the ways we manage them, are summarized in "Management's Discussion and Analysis of Financial Condition and Results of Operations", included in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes in the f…
⌄
Our market risks, and the ways we manage them, are summarized in "Management's Discussion and Analysis of Financial Condition and Results of Operations", included in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes in the first six months of 2026 to such risks or our management of such risks.
Information required for Part II, Item 1 is incorporated by reference to the discussion in Note 14 to the Consolidated Financial Statements (unaudited) included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
⌄
Information required for Part II, Item 1 is incorporated by reference to the discussion in Note 14 to the Consolidated Financial Statements (unaudited) included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
CNO and its businesses are subject to a number of risks including general business and financial risks. Any or all of such risks could have a material adverse effect on the business, financial condition or results of operations of CNO. Refer to "Risk Factors" in our Annual Repor…
⌄
CNO and its businesses are subject to a number of risks including general business and financial risks. Any or all of such risks could have a material adverse effect on the business, financial condition or results of operations of CNO. Refer to "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 for further discussion of such risk factors. There have been no material changes from such previously disclosed risk factors.